Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2020 November;86(11) > Minerva Anestesiologica 2020 November;86(11):1214-33

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

EXPERTS’ OPINION   Free accessfree

Minerva Anestesiologica 2020 November;86(11):1214-33

DOI: 10.23736/S0375-9393.20.14663-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Coronavirus disease 2019 in critically ill patients: can we re-program the immune system? A primer for Intensivists

Fiorenza FERRARI 1, 2 , Federico VISCONTI 1, Mara DE AMICI 3, Angelo GUGLIELMI 1, Costanza N. COLOMBO 1, Mirko BELLIATO 1, Claudio RONCO 2, 4, 5

1 Department of Anesthesia and Intensive Care Unit, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy; 2 Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy; 3 Immuno-Allergology Laboratory of the Clinical Chemistry Unit, IRCCS Polyclinic San Matteo Foundation, Pavia, Italy; 4 Unit of Nephrology, University of Padua, Padua, Italy; 5 Department Nephrology Dialysis and Transplant, AUSSL 8 Regione Veneto, San Bortolo Hospital, Vicenza, Italy



In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread around the word. The immune response is essential to control and eliminate CoV infections, however, multiorgan damage might be due to direct SARS-CoV2 action against the infected organ cells, as well as an imbalanced host immune response. In effect, a “cytokines storm” and an impaired innate immunity were found in the COVID-19 critically ill patients. In this review, we summarized the virus immune response steps, underlying the relevance of introducing the measurement of plasma cytokine levels and of circulating lymphocyte subsets in clinical practice for the follow-up of critically ill COVID-19 patients and support new therapy.


KEY WORDS: COVID-19; Severe acute respiratory syndrome; Cytokines; Immune system phenomena

top of page